Welcome to our dedicated page for Australis Cap news (Ticker: AUSAF), a resource for investors and traders seeking the latest updates and insights on Australis Cap stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Australis Cap's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Australis Cap's position in the market.
Australis Capital Inc. (CSE: AUSA, OTC: AUSAF) reported significant financial results for Q3 2021, ending December 31, 2020, with a net loss of $19.4 million, largely due to non-cash impairments and one-time expenses totaling $17.6 million. The company is poised for expansion with imminent acquisitions of ALPS and Green Therapeutics, expected to drive revenues significantly in Q4 2021 and beyond. New leadership has been appointed, and strategic efforts are underway to optimize operations and reduce costs. A conference call is set for March 2, 2021, to discuss results and future strategies.
Australis Capital entered a definitive agreement to acquire 51% of ALPS, with an option for an additional 49%. This strategic move aims to enhance AUSA's capital-light expansion strategy and generate immediate revenue growth, forecasted to exceed $5 million from signed contracts in the past month. Terry Booth will step in as CEO post-transaction. The deal includes milestone-based payments of up to $24 million, contingent on achieving specific revenue and EBITDA targets. The acquisition aligns with AUSA's focus on driving profitability in the burgeoning U.S. cannabis market.
Australis Capital Inc. (CSE: AUSA, OTC: AUSAF) is nearing the completion of two significant acquisitions: a 51% stake in ALPS and full ownership of Green Therapeutics. The latter acquisition resolves prior litigation. The Company anticipates closing the ALPS deal by February 22, 2021, followed by Green Therapeutics. Green Therapeutics is known for high-quality cannabis products with a 52% market penetration in Nevada. ALPS has secured contracts yielding over $5 million in revenue since the announcement of the transactions. The Company also appointed Clearview Capital Consult for investor relations.
Australis Capital Inc. (CSE: AUSA, OTC: AUSAF) announced a $1.9 million agreement for the development of a 62-acre high-tech greenhouse in California. This facility, being developed by ALPS through Larssen Greenhouse Consulting, aims to produce 48 million pounds of sustainable vegetables, significantly reducing water and labor usage by up to 90%. The project emphasizes local supply, enhancing food security and minimizing transportation emissions. The facility will also feature a 15 MW Co-Generation plant for sustainable energy and advanced automation for optimal growing conditions.
Australis Capital Inc. (AUSA) recently filed its Proxy Circular ahead of the Annual General & Special Meeting on November 17, 2020. The company urges shareholders to vote for its slate of director nominees to prevent a dissident group, led by Terry Booth, from taking control. The board highlights a strategic value creation plan focused on the U.S. cannabis market, new leadership, and cost-cutting measures. The dissidents' history raises concerns about potential self-enrichment and risks to shareholder value, particularly given their ties to Aurora Cannabis.
Australis Capital Inc. (CSE: AUSA, OTC: AUSAF) has appointed Harry DeMott as CEO, succeeding Cleve Tzung, who becomes COO. DeMott brings over 30 years of experience in the cannabis, media, and entertainment sectors. He aims to capitalize on the opportunities in the U.S. cannabis industry. Rick Cutler joins as an independent board member, enhancing AUSA's expertise in branded products. The company also announces the resignation of John Dover from the board. AUSA continues to focus on significant opportunities in the cannabis market, with assets including Cocoon Technology and Body and Mind Inc.
Australis Capital Inc. (CSE: AUSA; OTC: AUSAF) announced the appointment of Sameer Kumar as an independent Board member, enhancing its leadership with cannabis industry expertise. Kumar, former President and COO of VIOLA Brands, played a pivotal role in the company's growth, doubling production and increasing sales. This move is part of AUSA's strategy to focus on the U.S. cannabis market, intending to create value and better represent shareholder interests.
Australis Capital Inc. (CSE: AUSA, OTC: AUSAF) announced a delay in filing its executive compensation disclosure, relying on exemptions under BC Instrument 51-516. The company plans to include this disclosure in the information circular for its upcoming Annual General Meeting. AUSA focuses on investments in the cannabis industry, with assets like Cocoon Technology, a cloud-based point-of-sale solution, and investments in Body and Mind Inc., Quality Green, and Folium Biosciences.
Australis Capital Inc. (CSE: AUSA, OTC: AUSAF) has successfully installed its CocoonPod self-service kiosks at the THRIVE Cannabis Marketplace in North Las Vegas, marking the first of eight installations planned. This initiative aims to enhance customer experience amid COVID-19 by improving safety and efficiency during transactions. Cocoon's kiosks offer various functionalities, including online delivery and data analytics, designed to boost operational efficiency and revenue for dispensaries. The company emphasizes its commitment to U.S.-focused cannabis operations.
Australis Capital Inc. (CSE: AUSA, OTC: AUSAF) responded to a group of Concerned Shareholders seeking control of the Board. Initially demanding 100% control, the shareholders have now lowered their demand to 60% of Board seats, despite holding only ~7.9% of shares. AUSA's management, led by Harry DeMott, criticized the shareholders for inaccuracies in their claims and emphasized the company's renewed focus on the US cannabis market. The management remains open to collaboration but insists on the need for competent leadership that understands the cannabis landscape.
FAQ
What is the current stock price of Australis Cap (AUSAF)?
What is the market cap of Australis Cap (AUSAF)?
